AstraZeneca PLC
AZN
$171.34
-$1.96-1.13%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 2.33% | 5.62% | 55.07% | 77.26% | 27.14% |
| Total Depreciation and Amortization | 14.04% | 6.39% | 85.71% | -14.75% | 8.60% |
| Total Amortization of Deferred Charges | -- | -- | 18.00% | -- | -- |
| Total Other Non-Cash Items | -629.63% | -42.62% | -120.39% | 126.04% | -1,450.00% |
| Change in Net Operating Assets | -26.96% | -134.74% | -243.14% | 1,936.59% | -167.44% |
| Cash from Operations | -15.39% | -9.53% | -19.44% | 51.76% | 9.76% |
| Capital Expenditure | -15.78% | -27.51% | -46.33% | -64.51% | -72.51% |
| Sale of Property, Plant, and Equipment | -55.56% | 700.00% | 50.00% | -- | -- |
| Cash Acquisitions | 87.64% | 29.01% | 0.36% | -24.71% | 88.38% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -78.00% | -115.12% | 30.35% | -18.35% | -517.10% |
| Cash from Investing | -38.14% | -43.02% | -22.44% | -32.17% | 26.60% |
| Total Debt Issued | -101.86% | 293.45% | -76.92% | 15.18% | -57.12% |
| Total Debt Repaid | -2,107.83% | -12.94% | -1,671.43% | 95.54% | 95.76% |
| Issuance of Common Stock | 50.00% | 25.00% | 0.00% | 25.00% | -20.00% |
| Repurchase of Common Stock | -1,433.33% | -25.93% | -- | 76.54% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 90.00% | 1.79% | -- | -2.22% | 41.18% |
| Other Financing Activities | 100.00% | -169.23% | -1,178.26% | -112.50% | -- |
| Cash from Financing | -600.39% | 109.86% | -389.12% | 49.82% | 142.39% |
| Foreign Exchange rate Adjustments | -68.97% | -172.00% | 106.56% | -160.00% | 583.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -244.11% | 918.02% | -339.64% | 146.74% | 279.80% |